Efstratios Athanasiou*, Savvas Papageorgiou, Marianna Foteini Dafni, Ioannis Kelesis, Maria Vasileiou, Theodora Tatsiou, Vasiliki Kouveloglou, Panagiotis Kanatas, Ioannis Stouras, Athanasios Gatsis, Vasiliki Taxiarchoula Agiassoti, Petros Nasimpian, Dimitrios Dafnoudis, Kyriaki Degaita, Georgios Ioannis Verras, Athanasios Alexiou*, Marios Papadakis and Mohammad Amjad Kamal Pages 1 - 24 ( 24 )
Epidemiological trends in cancer research show that lung cancer can affect up to 1 in 15 men and 1 in 17 women. With incidence rates as high as these and significant associated mortality and morbidity, it is no wonder that lung cancer is one of the main areas of research focused on cancer. Advances in targeted treatments and specialized irradiation protocols have allowed the treatment of more advanced cases. However, as the patient numbers grow, so does the need for cancer-preventive strategies. The present narrative review focuses on soy isoflavones' role in the chemoprevention of lung cancer and their possible role in therapeutic adjuncts. Laboratory studies on lung cancer cell lines have shown that isoflavones can induce apoptosis, tamper with the expression of proliferative molecular pathways, and even reduce tumor angiogenesis. Additionally, population-level studies have emerged that correlate the consumption of isoflavonoids with reduced risk for the development of lung cancer. Interestingly enough, the literature also contains small-scale studies with evidence of isoflavones being effective chemotherapeutic adjuncts that are currently understudied. Our literature review underlines such findings and provides a call for the enhancement of research regarding naturally occurring dietary products with possible anticarcinogenic effects.
Natural compounds, soy products, phytochemicals, isoflavones, radiosensitization, lung cancer, chemoprevention.